摘要
目的:探讨健脾清热活血方对UC患者NLRP-6、Caspase-1及IL-18的变化。方法:将30例UC患者随机分为治疗组和对照组,治疗组给予健脾清热活血方,对照组给予美沙拉嗪颗粒剂,疗程为12周,应用肠镜下Baron评分、中医证候积分及NLRP-6、Caspase-1、IL-18表达变化评估两组疗效。结果:两组患者总体有效率相当,无显著差异;肠镜下Baron评分治疗后降低,组内前后比较有统计学意义,组间比较无显著性差异;两组患者中医证候积分治疗后均降低,治疗前与治疗后12周组内比有显著性性差异(P<0.05),组间比较无显著性差异;治疗后两组患者NLRP-6、Caspase-1、IL-18基因及免疫组化阳性细胞分布面积均降低,治疗后组内及组间比较均有统计学差异(P<0.05)。结论:健脾清热活血方可负向调节NLRP-6表达,抑制Caspase-1活化,下调IL-18表达,发挥治疗溃疡性结肠炎效用。
Objective:To investigate the changes of NLRP-6,Caspase-1,and IL-18 in patients with ulcerative colitis treated by Jianpi Jianpi Huoxue Formula.Methods:Thirty patients with ulcerative colitis were randomly divided into treatment group and control group,the treatment group was given Jianpi Qingre Huoxue Formula while the control group was treated with mesalazine granules.The course of the treatment was 12 weeks.The therapeutic effect of the two groups was evaluated by the Baron score under colonoscopy,TCM syndrome score and the expression of NLRP-6,Caspase-1,and IL-18.Results:There was no significant difference in the overall effective rate between the two groups;Baron score under colonoscopy decreased after the treatment,and there was no statistical difference between the two groups;after treatment,the scores of TCM syndromes decreased, there was a significant difference in the same group (P<0.05)and no significant difference when compared with the control group; after treatment,the expression of NLRP-6,Caspase-1,IL-18 gene and the number of immunohistochemical positive ceils were decreased in both groups,and there were significant differences between the two groups (P<0.05).Conclusion:Jianpi Qingre Huoxue Formula can negatively regulate the expression of NLRP-6,inhibit the activation of Caspase-1,and down-regulate the expression of IL-18,thus exerting its therapeutic effect on ulcerative colitis.
作者
陈良荣
绳荣湍
邱燕婷
宋杰
陈玉
马媛萍
方健松
刘畅
张涛
CHEN Liang-rong;SHENG Rong-tuan;QIU Yan-ting;SONG Jie;CHEN Yu;MA Yuan-ping;FANG Jian-song;LIU Chang;ZHANG Tao(Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Nanning 530011,China;The First People's Hospital of Zunyi Zunyi 563002,China;International Zhuang Medical Hospital of Guangxi,Nanning 530000,China;Guangxi Guiping Traditional Chinese Medicine Hospital,Gulping 537200,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2018年第12期5731-5734,共4页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
2016年广西中医药民族医药传承创新专项立项课题(临床研究类)(No.GZLC16-14).
